{"title":"治疗严重特应性过敏性疾病的 CAR T 细胞。","authors":"Ronald P Dudek, Zhengyu Ma","doi":"10.32481/djph.2023.11.004","DOIUrl":null,"url":null,"abstract":"<p><p>The prevalence of allergic diseases is rising rapdly in the US and the world. While antibody drugs and corticosteroids can provide symptom relief, they cannot cure allergic diseases. Described herein is a novel approach to treating severe atopic allergic diseases - chimeric antigen receptor-engineered T cells - that target and eliminate the cells that produce the causative agent of all atopic allergic diseases, immunoglubulin E (IgE).</p>","PeriodicalId":72774,"journal":{"name":"Delaware journal of public health","volume":"9 4","pages":"12-15"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10759977/pdf/","citationCount":"0","resultStr":"{\"title\":\"CAR T Cells for Treating Severe Atopic Allergic Diseases.\",\"authors\":\"Ronald P Dudek, Zhengyu Ma\",\"doi\":\"10.32481/djph.2023.11.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The prevalence of allergic diseases is rising rapdly in the US and the world. While antibody drugs and corticosteroids can provide symptom relief, they cannot cure allergic diseases. Described herein is a novel approach to treating severe atopic allergic diseases - chimeric antigen receptor-engineered T cells - that target and eliminate the cells that produce the causative agent of all atopic allergic diseases, immunoglubulin E (IgE).</p>\",\"PeriodicalId\":72774,\"journal\":{\"name\":\"Delaware journal of public health\",\"volume\":\"9 4\",\"pages\":\"12-15\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10759977/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Delaware journal of public health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32481/djph.2023.11.004\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/11/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Delaware journal of public health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32481/djph.2023.11.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
在美国和全世界，过敏性疾病的发病率急剧上升。虽然抗体药物和皮质类固醇可以缓解症状，但它们不能治愈过敏性疾病。本文介绍的是一种治疗严重特应性过敏性疾病的新方法--嵌合抗原受体工程化 T 细胞--可靶向消除产生所有特应性过敏性疾病致病因子免疫球蛋白 E (IgE) 的细胞。
CAR T Cells for Treating Severe Atopic Allergic Diseases.
The prevalence of allergic diseases is rising rapdly in the US and the world. While antibody drugs and corticosteroids can provide symptom relief, they cannot cure allergic diseases. Described herein is a novel approach to treating severe atopic allergic diseases - chimeric antigen receptor-engineered T cells - that target and eliminate the cells that produce the causative agent of all atopic allergic diseases, immunoglubulin E (IgE).
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
